Medivir AB (FRA:MVR0)
€ 0.229 0.007 (3.15%) Market Cap: 27.89 Mil Enterprise Value: 14.38 Mil PE Ratio: 0 PB Ratio: 2.14 GF Score: 53/100

Medivir AB R&D Day Transcript

Mar 02, 2020 / 01:00PM GMT
Release Date Price: €1.09 (+17.60%)
Uli Hacksell;publ;CEO
Medivir AB;President & Director

()- -

Good morning, and welcome to Medivir's R&D day. It's nice to see that so many of you have decided to come and listen to us live, but I know that we also have a lot of attendees that have connected through the web. I hope that we can offer you an exciting day, we think so. It will be a mix of educational and new data presentations. So I think the combination will really teach us a lot about liver cancer, a lot about MIV-818 and the opportunities that we see there and with other assets that we have.

Let me first say that it's good to take a look at this note and the forward-looking statements that are included in that. This is a slide that we always have, by the way. So the agenda today really starts with Dr. Evans, who will provide us with a lecture on primary liver cancer, and I'll come back to that later on. I think it's a great introduction of the day. Then Christina Herder, who is our EVP and Chief Operational Officer, will talk about the market for liver cancer drugs, which I think is

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot